Primecap Management Co. CA Reduces Holdings in Immunocore Holdings PLC Sponsored ADR $IMCR

Primecap Management Co. CA lowered its position in Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) by 0.4% during the third quarter, HoldingsChannel.com reports. The institutional investor owned 3,754,560 shares of the company’s stock after selling 16,914 shares during the quarter. Primecap Management Co. CA owned approximately 0.07% of Immunocore worth $136,403,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of IMCR. GAMMA Investing LLC increased its position in shares of Immunocore by 51.6% during the third quarter. GAMMA Investing LLC now owns 914 shares of the company’s stock worth $33,000 after acquiring an additional 311 shares during the last quarter. Elevation Point Wealth Partners LLC purchased a new stake in Immunocore during the 2nd quarter worth approximately $42,000. Osaic Holdings Inc. raised its position in shares of Immunocore by 117.4% in the 2nd quarter. Osaic Holdings Inc. now owns 3,148 shares of the company’s stock valued at $97,000 after purchasing an additional 1,700 shares in the last quarter. State of Tennessee Department of Treasury purchased a new position in shares of Immunocore during the 2nd quarter valued at approximately $132,000. Finally, Skandinaviska Enskilda Banken AB publ acquired a new stake in shares of Immunocore during the second quarter worth approximately $248,000. 84.50% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Immunocore

In related news, CEO Bahija Jallal sold 11,474 shares of the company’s stock in a transaction on Wednesday, February 18th. The stock was sold at an average price of $32.35, for a total transaction of $371,183.90. Following the completion of the transaction, the chief executive officer directly owned 12,343 shares in the company, valued at $399,296.05. This represents a 48.18% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider David M. Berman sold 5,965 shares of the stock in a transaction on Wednesday, February 18th. The stock was sold at an average price of $32.35, for a total value of $192,967.75. Following the completion of the sale, the insider directly owned 5,859 shares in the company, valued at $189,538.65. This represents a 50.45% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 19,137 shares of company stock worth $619,082 in the last 90 days. 10.40% of the stock is currently owned by company insiders.

Immunocore Trading Down 0.4%

NASDAQ IMCR opened at $32.04 on Friday. The firm has a market capitalization of $1.62 billion, a PE ratio of -45.77 and a beta of 0.78. Immunocore Holdings PLC Sponsored ADR has a one year low of $23.15 and a one year high of $40.71. The company has a 50-day simple moving average of $33.55 and a 200-day simple moving average of $34.32. The company has a debt-to-equity ratio of 0.99, a quick ratio of 5.97 and a current ratio of 6.00.

Immunocore (NASDAQ:IMCR) last issued its earnings results on Wednesday, February 25th. The company reported ($0.60) EPS for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.32). The company had revenue of $104.48 million during the quarter, compared to analyst estimates of $145.48 million. Immunocore had a negative net margin of 8.88% and a negative return on equity of 9.16%. The business’s revenue was up 24.3% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.47) earnings per share. On average, equities analysts forecast that Immunocore Holdings PLC Sponsored ADR will post -0.94 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research firms recently issued reports on IMCR. Mizuho set a $38.00 price target on shares of Immunocore in a report on Thursday, February 19th. HC Wainwright reaffirmed a “buy” rating and set a $100.00 price target on shares of Immunocore in a research report on Wednesday, February 4th. Wall Street Zen downgraded Immunocore from a “buy” rating to a “hold” rating in a research note on Saturday, January 31st. Wells Fargo & Company began coverage on Immunocore in a report on Friday, October 31st. They issued an “overweight” rating and a $60.00 price objective for the company. Finally, Morgan Stanley increased their target price on Immunocore from $34.00 to $36.00 and gave the stock an “equal weight” rating in a report on Monday, November 10th. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Immunocore presently has an average rating of “Moderate Buy” and a consensus price target of $61.30.

Immunocore News Roundup

Here are the key news stories impacting Immunocore this week:

• Positive Sentiment: Analyst upgrade and higher price target — Needham raised its price target from $71 to $75 and kept a Buy rating, implying substantial upside vs. the current share price. Benzinga
• Positive Sentiment: Strong product sales and cash runway — KIMMTRAK net sales were $104.5M in Q4 and $400M for FY2025; company ended the year with ~$864.2M in cash, cash equivalents and marketable securities, supporting R&D and runway. Press Release
• Positive Sentiment: Near-term clinical catalysts — Management expects TEBE‑AM enrollment completion 1H2026 with topline as early as 2H2026; multiple PRAME franchise and HIV Phase 1/2 readouts also slated in 2H2026 — potential value-inflecting events. Pipeline Update
• Neutral Sentiment: Full earnings materials available — Management hosted a conference call and released slide deck and transcripts; these provide color on commercialization, trial timelines and cost structure. Earnings Transcript
• Negative Sentiment: Quarterly misses and guidance tone — Q4 EPS of ($0.60) missed consensus (~($0.28)) and revenue of $104.48M materially missed the ~$145M estimate; company cautioned that revenue growth will moderate in 2026, which reduces near-term upside. Earnings Release / Slide Deck

About Immunocore

Immunocore plc is a clinical‐stage biotechnology company focused on the development of novel immunotherapies that harness the body’s own T‐cell response to treat cancer and infectious diseases. The company’s proprietary ImmTAC (immune mobilising monoclonal T‐cell receptors against cancer) platform utilizes engineered, soluble T‐cell receptor (TCR) molecules designed to recognise intracellular peptide–HLA complexes. By redirecting and activating T cells against disease‐associated targets, Immunocore aims to address malignancies and persistent viral infections with high unmet medical need.

The company’s most advanced candidate, tebentafusp, is a bispecific ImmTAC molecule that targets gp100, a melanoma‐associated antigen, and has received regulatory approval for the treatment of metastatic uveal melanoma.